rga9 Antibody
Description
Mechanism of Action
The RG9-1 antibody (Clone RG9-1) binds specifically to mouse Galectin-9, a protein expressed by diverse immune and stromal cells, including T cells, macrophages, and dendritic cells . Galectin-9 modulates immune responses by interacting with TIM-3 (T-cell immunoglobulin and mucin domain-3), a receptor that induces T-cell exhaustion and apoptosis when engaged . By blocking this interaction, RG9-1 prevents Galectin-9-mediated immunosuppression, thereby enhancing anti-tumor immunity.
| Characteristic | Detail |
|---|---|
| Clone | RG9-1 |
| Isotype | Rat IgG2b κ |
| Reactivity | Mouse Galectin-9 |
| Endotoxin Level | ≤0.5 EU/mg (LAL method) |
| Purity | ≥95% (SDS-PAGE), ≥98% monomer (SEC) |
| Applications | Blocking, in vivo studies |
Preclinical Efficacy
Recent studies highlight the RG9-1 antibody’s therapeutic potential in cancer models:
-
Pancreatic Ductal Adenocarcinoma (PDAC): RG9-1 monotherapy delayed tumor progression and extended survival in PDAC mouse models .
-
Triple-Negative Breast Cancer (TNBC): Synergy with glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) agonists enhanced tumor suppression .
-
Colorectal Cancer: Combination therapy with anti-GITR antibodies demonstrated robust anti-tumor activity, underscoring Galectin-9’s role in immune evasion .
| Model | Treatment | Outcome |
|---|---|---|
| PDAC | RG9-1 monotherapy | Slowed tumor growth, improved survival |
| TNBC | RG9-1 + GITR agonist | Enhanced tumor suppression |
| Colorectal Cancer | RG9-1 + GITR agonist | Synergistic anti-tumor effects |
Therapeutic Applications
Galectin-9 inhibition represents a novel immune checkpoint strategy distinct from PD-1/CTLA-4 blockade . Key advantages include:
-
Broad Tumor Applicability: Galectin-9 is overexpressed in multiple cancers, including renal cell carcinoma and melanoma .
-
Combination Potential: Synergy with checkpoint inhibitors and costimulatory agonists (e.g., GITR, 4-1BB) offers a rationale for combinatorial regimens .
Future Directions
While RG9-1 remains in preclinical development, its success in mouse models warrants further investigation:
-
Humanized Variants: Development of human Galectin-9 antibodies (e.g., Clone 292-4) has shown promise in vitro, protecting T cells from apoptosis .
-
Clinical Translation: Ongoing efforts aim to evaluate Galectin-9 targeting in solid tumors, leveraging its mechanism to overcome resistance to existing immunotherapies .
References
-
Assay Genie. (2025). Anti-Mouse Galectin-9 (Clone RG9-1) In Vivo Antibody - Ultra Low Endotoxin. Retrieved from Assay Genie
-
PMC. (2022). Development and characterization of anti-galectin-9 antibodies. Retrieved from PubMed Central
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
KEGG: spo:SPAC1952.16
STRING: 4896.SPAC1952.16.1
